Development and validation of a risk scoring system to predict surgical-site infection after soft-tissue sarcoma resectio
Not Applicable
- Conditions
- Soft tissue sarcoma
- Registration Number
- JPRN-jRCT1040220108
- Lead Sponsor
- Miwa Shinji
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Patients with STS who underwent surgical resection in Kanazawa University Hospital.
Exclusion Criteria
Patients with incomplete information regarding the clinical parameter or treatment of the patients.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers are associated with surgical-site infection risk in soft tissue sarcoma patients post-resection?
How does the risk scoring system in JPRN-jRCT1040220108 compare to existing predictive models for postoperative infections in sarcoma surgery?
Are there specific immune response pathways linked to surgical-site infections after soft tissue sarcoma resection?
What are the most effective prophylactic antibiotic regimens for preventing surgical-site infections in high-risk soft tissue sarcoma cases?
How do patient comorbidities and tumor characteristics influence surgical-site infection rates in soft tissue sarcoma resection studies?